Cybrexa Regains Rights to CBX-12 NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...

Cybrexa Therapeutics to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference NEW HAVEN, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...

Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021 NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...